-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E3SHnX/zpScg2/Gp62uDn0aS5sDa6wAfatX2Kmt5L7CVgeQ2V5aujR+bwJFGfzpe MPvjdZk5tnH99SPsVbtlwg== 0000950133-04-000442.txt : 20040217 0000950133-04-000442.hdr.sgml : 20040216 20040217105141 ACCESSION NUMBER: 0000950133-04-000442 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040217 GROUP MEMBERS: BIOTECH GROWTH N.V. GROUP MEMBERS: BIOTECH TARGET N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: VIROLOGIC INC CENTRAL INDEX KEY: 0001094961 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943234479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-59123 FILM NUMBER: 04604772 BUSINESS ADDRESS: STREET 1: 345 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.635.1100 MAIL ADDRESS: STREET 1: 345 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 SC 13G/A 1 w94235asc13gza.txt AMENDMENT NO. 2 ---------------------------- OMB APPROVAL ---------------------------- OMB Number: 3235-0145 ---------------------------- Expires: December 31, 2005 ---------------------------- Estimated average burden hours per response... 11 ---------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* VIROLOGIC, INC. ------------------------------------------------------------ (Name of Issuer) COMMON STOCK ------------------------------------------------------------ (Title of Class of Securities) 92823R201 ------------------------------------------------------------ (CUSIP Number) DECEMBER 31, 2003 ------------------------------------------------------------ (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed " for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 7 CUSIP No. 92823R201 -------------------------- 1. Names of Reporting Persons BB BIOTECH AG -------------------------------------------- I.R.S. Identification Nos. of above persons (entities only): N/A ---------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) [ ] 3. SEC Use Only -------------------------------------------------------- 4. Citizenship or Place of Organization SWITZERLAND --------------------------------- Number of Shares Beneficially 5. Sole Voting Power 0 Owned by Each Reporting -------------------- Person with: 6. Shared Voting Power 5,726,430 ------------------ 7. Sole Dispositive Power 0 --------------- 8. Shared Dispositive Power 6,717,423(1) ------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,717,423(1) --------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ] 11. Percent of Class Represented by amount in Row (9) 15.1% -------------------- 12. Type of Reporting Person (See Instructions) HC,CO -------------------------- (1) Includes 990,993 shares of Common Stock issuable to Biotech Target N.V. upon the exercise of warrants. Page 2 of 7 CUSIP No. 92823R201 ---------------------------------- 1. Names of Reporting Persons BIOTECH GROWTH N.V. ------------------------------------------- I.R.S. Identification Nos. of above persons (entities only): N/A --------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) [ ] 3. SEC Use Only -------------------------------------------------------- 4. Citizenship or Place of Organization NETHERLANDS ANTILLES --------------------------------- Number of Shares Beneficially 5. Sole Voting Power 0 Owned by Each Reporting ------------------- Person with: 6. Shared Voting Power 5,726,430 ----------------- 7. Sole Dispositive Power 0 -------------- 8. Shared Dispositive Power 6,717,423(1) ------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,717,423(1) --------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ] 11. Percent of Class Represented by amount in Row (9) 15.1% -------------------- 12. Type of Reporting Person (See Instructions) CO -------------------------- (1) Includes 990,993 shares of Common Stock issuable to Biotech Target N.V. upon the exercise of warrants. Page 3 of 7 CUSIP No. 92823R201 --------------------------- 1. Names of Reporting Persons BIOTECH TARGET N.V. ------------------------------------------- I.R.S. Identification Nos. of above persons (entities only): N/A ---------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) [ ] 3. SEC Use Only -------------------------------------------------------- 4. Citizenship or Place of Organization NETHERLANDS ANTILLES --------------------------------- Number of Shares Beneficially 5. Sole Voting Power 0 Owned by Each Reporting ------------------- Person with: 6. Shared Voting Power 5,726,430 ------------------ 7. Sole Dispositive Power 0 -------------- 8. Shared Dispositive Power 6,717,423(1) ------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,717,423(1) --------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ] 11. Percent of Class Represented by amount in Row (9) 15.1% -------------------- 12. Type of Reporting Person (See Instructions) CO -------------------------- (1) Includes 990,993 shares of Common Stock issuable to Biotech Target N.V. upon the exercise of warrants. page 4 of 7 ITEM 4. OWNERSHIP Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 6,717,423(1) -------------------------------------------- (b) Percent of class: 15.1% ---------------------------------------------------- (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote ----------------------- (ii) Shared power to vote or to direct the vote 5,726,430 --------------------- (iii) Sole power to dispose or to direct the disposition of ---------- (iv) Shared power to dispose or to direct the disposition of 6,717,423(1) -------------------------------- (1) Includes 990,993 shares of Common Stock issuable to Biotech Target N.V. upon the exercise of warrants. Page 5 of 7 ITEM 10. CERTIFICATION By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG /s/ ROLAND MAIER /s/ ADRIAN BRUENGGER - ----------------------------------- -------------------------------------- By: Roland Maier By: Adrian Bruengger Its: Authorized Signatory Its: Authorized Signatory Date: February 17, 2004 Date: February 17, 2004 BIOTECH GROWTH N.V. /s/ ROLAND MAIER /s/ ADRIAN BRUENGGER - ----------------------------------- -------------------------------------- By: Roland Maier By: Adrian Bruengger Its: Authorized Signatory Its: Authorized Signatory Date: February 17, 2004 Date: February 17, 2004 BIOTECH TARGET N.V. /s/ ROLAND MAIER /s/ ADRIAN BRUENGGER - ----------------------------------- -------------------------------------- By: Roland Maier By: Adrian Bruengger Its: Authorized Signatory Its: Authorized Signatory Date: February 17, 2004 Date: February 17, 2004 Page 6 of 7 EXHIBIT INDEX ------------- Exhibit 1: Agreement by and among BB Biotech, BioGrowth and BioTarget with respect to the filing of this disclosure statement.* - ---------------------- * Previously filed. Page 7 of 7 -----END PRIVACY-ENHANCED MESSAGE-----